Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesReimbursement/Payment PolicyBCBS Texas Coronavirus Testing Update | OpenPayer
    Ask Trek AI about this page
    ModifiedBlue Cross Blue Shield - TexasPolicy RPLAB057

    Coronavirus Testing in the Outpatient Setting

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Texas Policy RPLAB057 alerts

    Get alerted when Policy RPLAB057 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs reimbursement for SARS-CoV-2 and related coronavirus testing performed for medical decision making in the outpatient setting. It applies to providers submitting claims to Blue Cross Blue Shield of Texas, subject to the member’s plan documents and provider contract.

    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyCoronavirus Testing in the Outpatient Setting
    Policy CodePolicy RPLAB057
    Change TypeModified
    Effective DateDecember 4, 2026
    Next Review DateN/A
    Key ActionApply the 48-hour limit for symptomatic SARS-CoV-2 antigen diagnostic testing.
    SourceLink
    POLICY UPDATE CHANGES

    The December 4, 2026 update revised Reimbursement Information Notes 1, 2, and 3 to align with updated CDC definitions for COVID-19, MIS-C, and MIS-A.

    The July 25, 2025 update added NAAT as an acceptable test option for MIS-A and MIS-C and revised the related language for clarity.

    The July 25, 2025 update revised testing frequency to include testing once every 48 hours.

    The July 25, 2025 update removed the provision for asymptomatic individuals before immunosuppressive or aerosol-producing procedures.

    The July 25, 2025 update removed items addressing whole genome sequencing and other numbered reimbursement provisions, including items 6, 7, 8, and 10 as described in the history.

    The July 25, 2025 update removed codes 86318, 86790, 87428, 87631, 87632, 87633, 87797, 87799, 0115U, 0202U, 0223U, 0225U, and C9803.

    The December 4, 2026 update revised the policy references.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    48 hoursSymptomatic antigen testing frequency
    90 daysPrior infection lookback for asymptomatic exposed individuals
    Not reimbursableSARS-CoV-2 neutralization antibody testing
    Not reimbursableEndemic coronavirus testing
    <21 / 21+MIS-C and MIS-A age thresholds
    13Codes removed in July 2025 update

    Reimbursement Eligibility

    Targeted COVID-19 nucleic acid testing

    Targeted nucleic acid testing may be reimbursable when at least one of the following applies:

    ONE of

    • ALL of the following

      • The individual displays signs or symptoms of possible COVID-19 infection.
    • ALL of the following

      • The individual is asymptomatic.
      • The individual has known exposure to COVID-19.
      • The individual has not had a previous COVID-19 infection within the last 90 days.

    SARS or MERS nucleic acid testing

    Targeted nucleic acid testing may be reimbursable when the applicable clinical symptoms and epidemiologic history are both present:

    ONE of

    • ALL of the following

      • The individual has signs or symptoms of severe acute respiratory syndrome (SARS).
      • The individual has traveled to an endemic area or has been exposed to a person with SARS.
    • ALL of the following

      • The individual has signs or symptoms of Middle East respiratory syndrome (MERS).
      • The individual has traveled to an endemic area or has been exposed to a person with MERS.

    Testing for MIS-C, MIS-A, or PASC

    Nucleic acid amplification testing and host serology testing may be reimbursable when performed to support a diagnosis of one of the following:

    ONE of

    • Multisystem inflammatory syndrome in children (MIS-C).
    • Multisystem inflammatory syndrome in adults (MIS-A).
    • Post-acute sequelae of SARS-CoV-2 infection (PASC).

    Symptomatic SARS-CoV-2 antigen testing

    Antigen-detecting SARS-CoV-2 diagnostic testing may be reimbursable when both conditions are met:

    ALL of the following

    • The individual is symptomatic.
    • Testing is performed no more than once every 48 hours.Once every 48 hours

    Non-reimbursable testing

    Testing is not reimbursable when any of the following applies:

    ANY of

    • Host antibody serology testing is performed for a situation not otherwise described as reimbursable.
    • Neutralization antibody testing for SARS-CoV-2 is performed.
    • Testing is for an endemic coronavirus, including 229E, NL63, OC43, or HKU1.

    Covered and Non-Covered Codes

    SARS-CoV-2 antigen diagnostic testsCPTCovered
    87426SARS-CoV-2 coronavirus antigen immunoassay
    87811SARS-CoV-2 COVID-19 antigen test with optical reading
    SARS-CoV-2 and related nucleic acid amplification testingmixedCovered
    87635SARS-CoV-2 COVID-19 amplification probe test
    87798Detection of infectious agent by nucleic acid amplification, not otherwise specified
    U00012019-nCoV diagnostic test
    U0002COVID-19 laboratory test, non-CDC
    Host antibody serology testingmixedNot Covered
    86328Immunoassay for SARS-CoV-2 antibody
    86413SARS-CoV-2 antibody quantitative test
    86769SARS-CoV-2 COVID-19 antibody test
    0224USARS-CoV-2 antibody titer(s)
    0408USARS-CoV-2 antibody assay
    SARS-CoV-2 neutralization antibody testingmixedNot Covered
    86408SARS-CoV-2 neutralizing antibody screen
    86409SARS-CoV-2 neutralizing antibody titer
    0226USARS-CoV-2 surrogate virus neutralization test by ELISA
    Other listed molecular detection codeCPT
    87798Detection of agent by DNA amplification, not otherwise specified
    Codes removed in the July 25, 2025 policy updatemixedNot Covered
    86318Code listed as removed from the policy
    86790Code listed as removed from the policy
    87428Code listed as removed from the policy
    87631Code listed as removed from the policy
    87632Code listed as removed from the policy
    87633Code listed as removed from the policy
    87797Code listed as removed from the policy
    87799Code listed as removed from the policy
    0115UCode listed as removed from the policy
    0202UCode listed as removed from the policy
    1–10 of 13
    1/2
    Prior COVID-19 Infection Exclusion
    PopulationAsymptomatic individuals with known exposure to COVID-19
    Prior infection ruleNo reimbursement exception when the individual had a previous COVID-19 infection within the last 90 days
    Testing typeTargeted nucleic acid testing for COVID-19 may be reimbursable
    Symptomatic Antigen Testing Frequency
    PopulationSymptomatic individuals
    Testing type

    Billing and Documentation Actions

    Documentation Required

    Submit accurate coding and documentation

    Submit accurate documentation of services performed and use valid code combinations from Health Insurance Portability and Accountability Act-approved code sets. Claims should be coded appropriately according to applicable industry-standard coding guidelines.

    Documentation Required

    Respond to claim documentation requests

    Be prepared to submit additional documentation upon request. Claims may undergo claim review, code edits, benefit review, contract review, medical policy review, reimbursement policy review, and coding software review.

    Clinical Definitions and Thresholds

    Possible COVID-19 Infection Symptoms
    Respiratory symptomsShortness of breath or difficulty breathing; congestion or runny nose; sore throat
    Systemic symptomsFever, chills, fatigue, and muscle or body aches
    Other possible symptomsCough, new loss of taste or smell, nausea, vomiting, and diarrhea
    MIS-C Definition
    Age and feverIllness in a person less than 21 years of age with subjective or documented fever of at least 38°C
    Severity and inflammationClinical severity requiring hospitalization and CRP at least 3.0 mg/dL (30 mg/L)
    Organ involvement
    Policy Summary
    PayerBlue Cross Blue Shield - Texas
    PolicyCoronavirus Testing in the Outpatient Setting
    Policy CodePolicy RPLAB057
    Change TypeModified
    Effective DateDecember 4, 2026
    Next Review DateN/A
    Key ActionApply the 48-hour limit for symptomatic SARS-CoV-2 antigen diagnostic testing.
    SourceLink
    On This Page
    Reimbursement EligibilityCovered and Non-Covered CodesBilling and Documentation ActionsClinical Definitions and Thresholds
    Antigen-detecting diagnostic tests for SARS-CoV-2
    Frequency limitOnce every 48 hours
    MIS-C Age Threshold
    ConditionMultisystem inflammatory syndrome in children (MIS-C)
    Age thresholdLess than 21 years of age
    Required contextClinical severity requiring hospitalization
    MIS-C Fever Threshold
    ConditionMIS-C requires a subjective or documented fever
    Temperature thresholdAt least 38°C
    MIS-A timingFor MIS-A, qualifying fever occurs for 24 or more hours before hospitalization or within the first 3 days of hospitalization
    MIS-C Systemic Inflammation
    ConditionMIS-C systemic inflammation
    MarkerC-reactive protein (CRP)
    ThresholdAt least 3.0 mg/dL (30 mg/L)
    MIS-A Age Threshold
    ConditionMultisystem inflammatory syndrome in adults (MIS-A)
    Age threshold21 years of age or older
    Required settingHospitalization for 24 hours or more
    MIS-A Hospitalization Requirement
    ConditionMIS-A
    Hospitalization requirementHospitalization for 24 hours or more
    Fever timingFever must occur for 24 or more hours before hospitalization or within the first 3 days of hospitalization
    MIS-A Qualifying Clinical Findings
    Minimum findingsAt least three qualifying clinical findings
    Primary criterionAt least one finding must be a primary clinical criterion
    TimingFindings must occur before hospitalization or within the first three days of hospitalization
    Testing Frequency
    Applicable testingSymptomatic SARS-CoV-2 antigen-detecting diagnostic testing
    FrequencyOnce every 48 hours
    Policy contextThe July 25, 2025 update revised the testing frequency provision to include once every 48 hours
    Billing Rule

    Verify product-specific requirements

    Review the applicable Plan documents before billing because laboratory management reimbursement criteria may differ by product, and not all requirements apply to every product.

    Billing Rule

    Bill targeted SARS-CoV-2 molecular testing only for eligible indications

    Bill targeted SARS-CoV-2 nucleic acid testing only when the patient displays signs or symptoms of possible COVID-19, or is asymptomatic with known exposure to COVID-19 and has not had a previous COVID-19 infection within the last 90 days.

    Documentation Required

    Support SARS or MERS testing with clinical indication and exposure history

    Support targeted SARS or MERS nucleic acid testing with compatible signs or symptoms and the required epidemiologic history. The patient must have traveled to an endemic area or been exposed to a person with SARS or MERS, as applicable.

    Documentation Required

    Support testing for post-COVID inflammatory or sequela conditions

    Document that nucleic acid amplification testing or host serology testing is being performed to support a diagnosis of MIS-C, MIS-A, or PASC. The relevant clinical indication must be supported in the medical record.

    Billing Rule

    Apply the 48-hour symptomatic antigen testing limit

    For symptomatic individuals, bill antigen-detecting SARS-CoV-2 diagnostic testing no more than once every 48 hours. Testing once every 48 hours may be reimbursable.

    Denial Risk

    Avoid unsupported host antibody serology claims

    Do not expect reimbursement for host antibody serology testing when the situation is not one of the policy-described indications. Such testing is not reimbursable for all other situations.

    Denial Risk

    Do not bill neutralization antibody testing as reimbursable

    Do not bill SARS-CoV-2 neutralization antibody testing as reimbursable. Neutralization antibody testing is not reimbursable in any situation.

    Denial Risk

    Exclude endemic coronavirus testing

    Exclude testing for endemic coronaviruses from reimbursable claims. Testing for 229E, NL63, OC43, and HKU1 is not reimbursable.

    Documentation Required

    Consult related pathogen panel testing policy

    For items identified as managed by the Pathogen Panel Testing policy, consult CPCPLAB045 before submitting the claim.

    New manifestations in at least two categories, including cardiac, mucocutaneous, shock, gastrointestinal, or hematologic involvement
    MIS-A Definition
    Age and hospitalizationIllness in a person 21 years of age or older requiring hospitalization for 24 hours or more
    Required findingsQualifying fever, at least three clinical criteria with at least one primary criterion, and evidence of systemic inflammation
    Exclusions and infection evidenceNo alternative diagnosis; evidence of SARS-CoV-2 infection is required
    MIS-C Cardiac Involvement
    Left ventricular functionLeft ventricular ejection fraction below 55%
    Coronary findingsCoronary artery dilatation, aneurysm, or ectasia
    Cardiac biomarkerElevated troponin
    MIS-C Mucocutaneous Involvement
    Skin findingRash
    Oral and ocular findingsInflammation of the oral mucosa, conjunctivitis, or conjunctival injection
    Extremity findingsErythema or edema of the hands or feet
    MIS-C Hematologic Involvement
    Platelet criterionPlatelet count below 150,000 cells/µL
    Lymphocyte criterionAbsolute lymphocyte count (ALC) below 1,000 cells/µL
    Clinical categoryThese findings indicate hematologic involvement in MIS-C
    MIS-A Primary Clinical Criteria
    Primary criterion 1Severe cardiac illness, such as myocarditis, pericarditis, coronary artery dilation or aneurysm, new-onset ventricular dysfunction, second- or third-degree A-V block, or ventricular tachycardia
    Primary criterion 2Rash and non-purulent conjunctivitis
    Use in MIS-A definitionAt least one primary clinical criterion is required among at least three qualifying clinical findings
    MIS-A Secondary Clinical Criteria
    NeurologicNew-onset neurologic signs or symptoms, including encephalopathy, seizures, meningeal signs, or peripheral neuropathy such as Guillain-Barré syndrome
    HemodynamicShock or hypotension not attributable to medical therapy
    GastrointestinalAbdominal pain, vomiting, or diarrhea
    HematologicThrombocytopenia with platelet count below 150,000/µL